FindTrial
Sign In

Emotional distress in breast cancer patients during chemotherapy

Observational study to evaluate the trends of emotional distress and quality of life throughout chemotherapy cycles of breast cancer patients receiving Adriamycin/Epirubicin and Cyclophosphamide regimen at a tertiary care cancer center in central India - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/03/083067
Enrollment
30
Registered
2025-03-21
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50-C50- Malignant neoplasms of breast

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

HCG Cancer Center Nagpur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Stage I, II, and III and locally advanced breast cancer patients receiving neo-adjuvant or adjuvant AC/EC regimen based chemotherapy Between 18 and 65 years of age Functional ability as per ECOG (Eastern Cooperative Oncology Group) score 0 to 3 Patients consenting to participate in the study

Exclusion criteria

Exclusion criteria: Patients planned for chemotherapy regimen other than AC/EC Recurrence Palliative chemotherapy Extreme cognitive impairments Major psychiatric disorder

Design outcomes

Primary

MeasureTime frame
Emotional distress and quality of lifeTimepoint: Baseline, 3 weeks, 6 weeks and 9 weeks.—

Secondary

MeasureTime frame
Not applicableTimepoint: Not applicable—

Countries

India

Contacts

Public ContactDr Shrutika Kamdi

HCG Cancer Center, Nagpur

shrutidube08@gmail.com9665094981

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026